Lupin Thailand is a joint venture between the GP group of Thailand in which Lupin group holds a majority seventy per cent stake while the GP group holds the balance thirty per cent. As per the plan, Lupin Labs will infuse approximately Rs 2 crore to partially convert its bulk drug manufacturing facility into a specialty chemicals plant.
Specialty chemicals is a segment presently witnessing a demand spurt in Thailand.
Lupin will commence marketing of such products from third quarter of current financial year. According to a recent report prepared by Dun and Bradstreet, these two countries have around eight times more disposable income for personal care products as compared to India. Lupin Labs will however continue with the manufacture of some of its key bulk drugs like erythromycin salts and pyrazinamide. While Lupin Thailand is the largest manufacturer of pyrazinamide in the world, it is the second largest producer of erythromycin with capacities up to 200 tonnes every year. Abbott is the world leader in erythromycin production.